Solventum (NYSE:SOLV) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded Solventum from “hold” to “buy,” while the broader analyst consensus remains “Moderate Buy,” with an average price target of $92.80.
• Several analysts recently raised their price targets, including KeyCorp to $102, UBS Group to $101, Stifel Nicolaus to $100, and Mizuho setting a $113 target.
• Solventum reported quarterly EPS of $2.55, beating estimates by $0.64, while revenue reached $2.21 billion, up 2.2% year over year and above consensus expectations.

Solventum (NYSE:SOLV - Get Free Report) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued on Saturday, Wall Street Zen reports.

Other analysts have also recently issued reports about the stock. KeyCorp upped their price target on shares of Solventum from $93.00 to $102.00 and gave the stock an "overweight" rating in a research report on Thursday, August 6th. UBS Group raised their price objective on Solventum from $95.00 to $101.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Stifel Nicolaus upped their target price on Solventum from $90.00 to $100.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. BTIG Research upped their target price on Solventum from $91.00 to $95.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. Finally, Mizuho set a $113.00 target price on Solventum in a research note on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $92.80.

Solventum Trading Down 0.3%

Shares of SOLV stock opened at $87.43 on Friday. The stock has a market cap of $14.88 billion, a price-to-earnings ratio of 10.69, a price-to-earnings-growth ratio of 1.37 and a beta of 0.61. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 1.00. Solventum has a fifty-two week low of $62.38 and a fifty-two week high of $94.16. The firm's 50 day moving average price is $85.15 and its two-hundred day moving average price is $76.55.

Solventum (NYSE:SOLV - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.64. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The company had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.15 billion. During the same period in the previous year, the firm earned $1.69 earnings per share. Solventum's revenue for the quarter was up 2.2% on a year-over-year basis. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. On average, analysts anticipate that Solventum will post 7.22 EPS for the current year.

Institutional Investors Weigh In On Solventum

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sequoia Financial Advisors LLC lifted its holdings in Solventum by 18.7% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 21,672 shares of the company's stock worth $1,672,000 after buying an additional 3,412 shares in the last quarter. MCF Advisors LLC increased its position in shares of Solventum by 2,497.7% during the second quarter. MCF Advisors LLC now owns 1,143 shares of the company's stock worth $88,000 after acquiring an additional 1,099 shares during the last quarter. WINTON GROUP Ltd purchased a new stake in shares of Solventum during the second quarter worth about $3,402,000. Engineers Gate Manager LP purchased a new stake in shares of Solventum during the second quarter worth about $1,881,000. Finally, Integrated Wealth Concepts LLC lifted its stake in shares of Solventum by 7.1% in the second quarter. Integrated Wealth Concepts LLC now owns 9,052 shares of the company's stock worth $698,000 after acquiring an additional 597 shares in the last quarter.

About Solventum

Solventum Corporation NYSE: SOLV is a global healthcare company that develops products and technologies intended to improve patient care, support healthcare professionals and increase the efficiency of healthcare delivery. The company serves hospitals, clinics, dental practices, laboratories, government agencies and other healthcare-related organizations.

Its offerings include medical and surgical products such as wound-care, skin-care, infection-prevention and surgical solutions; dental products and materials; and health information systems that support clinical documentation, coding, workflow and decision-making.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.